Frates joins Amylyx following his tenure as CFO at Alkermes, since 1998.
Frates is an experienced leader who served as Alkermes CFO through its growth from a clinical stage company to an international commercial and development enterprise with multiple products, over USD 1bn in revenue and over 2000 employees.
Frates helped manage the company through numerous acquisitions and financings in the debt, equity and private markets. Prior to Alkermes, Frates worked as an investment banker at Robertson, Stephens and company and Morgan Stanley.
Frates currently serves on the board of Sage Therapeutics, Inc., The Roxbury Latin School and St. Francis House in Boston. He is a graduate of Harvard College and earned an MBA from the Harvard Graduate School of Business Administration.
Amylyx Pharmaceuticals is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis, Alzheimer's disease and other neurodegenerative diseases.
Biller Named to Rome Therapeutics Board of Directors
Beck Named Chief Financial Officer at 4D Pharma
Gyroscope Therapeutics names Jessica Stitt as CFO
Campanelli Named to Slayback Board of Directors
Zhang Named Chief Medical Officer at InnoCare
The University of Health Sciences and Pharmacy in St Louis names new president
New COVID-19 virus variant discovered in New York City and Northeast US
NovellusDx Establishes Fore Biotherapeutics US as its Operating company in the United States
Dhingra Named Chairman of the Board of Directors at Lava Therapeutics